{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:23:42Z","timestamp":1761956622138,"version":"build-2065373602"},"reference-count":205,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1053\/j.seminhematol.2008.09.004","type":"journal-article","created":{"date-parts":[[2008,12,20]],"date-time":"2008-12-20T04:27:52Z","timestamp":1229747272000},"page":"89-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunotherapy in Acute Leukemia"],"prefix":"10.1053","volume":"46","author":[{"given":"Wing","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2008.09.004_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nm0303-269","article-title":"Immunotherapy: past, present and future","volume":"9","author":"Waldmann","year":"2003","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ijc.1608","article-title":"Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma","volume":"97","author":"Kao","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib3","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1056\/NEJMoa065497","article-title":"Case-control study of human papillomavirus and oropharyngeal cancer","volume":"356","author":"D'Souza","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib4","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00003086-199101000-00002","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas","volume":"262","author":"Coley","year":"1991","journal-title":"Clin Orthop Relat Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/357011a0","article-title":"Coley's toxins in perspective","volume":"357","author":"Starnes","year":"1992","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody","volume":"306","author":"Miller","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/nbt1007-1097","article-title":"What's fueling the biotech engine?","volume":"25","author":"Aggarwal","year":"2007","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000386035","article-title":"The concept of immunological surveillance","volume":"13","author":"Burnet","year":"1970","journal-title":"Prog Exp Tumor Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib11","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1073\/pnas.95.13.7556","article-title":"Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice","volume":"95","author":"Kaplan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib13","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib14","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.4049\/jimmunol.176.9.5354","article-title":"Murine model of immune-mediated rejection of the acute lymphoblastic leukemia 70Z\/3","volume":"176","author":"Labbe","year":"2006","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib16","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib18","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1056\/NEJMra072739","article-title":"Cancer immunology","volume":"358","author":"Finn","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib19","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.healun.2007.05.019","article-title":"Incidence of malignancies in heart and\/or lung transplant recipients: a single-institution experience","volume":"26","author":"Roithmaier","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib20","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib21","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/0008-5472.CAN-06-3388","article-title":"High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer","volume":"67","author":"Piersma","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib23","first-page":"3491","article-title":"CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer","volume":"58","author":"Naito","year":"1998","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib24","first-page":"3932","article-title":"Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas","volume":"61","author":"Schumacher","year":"2001","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1349-7006.2003.tb01392.x","article-title":"CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers","volume":"94","author":"Wakabayashi","year":"2003","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib26","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0020284","article-title":"Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer","volume":"2","author":"Kohrt","year":"2005","journal-title":"PLoS Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib27","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1073\/pnas.0611618104","article-title":"CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma","volume":"104","author":"Sharma","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib28","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib29","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(00)03231-1","article-title":"Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population","volume":"356","author":"Imai","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib30","first-page":"410","article-title":"Immunotherapy in acute leukemias","volume":"3","author":"Mahoney","year":"1981","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib31","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.leukres.2007.11.036","article-title":"Improving treatment strategies for acute lymphoblastic leukemia by combining immunotherapy and chemotherapy","volume":"32","author":"Gojo","year":"2008","journal-title":"Leuk Res"},{"issue":"2","key":"10.1053\/j.seminhematol.2008.09.004_bib32","doi-asserted-by":"crossref","first-page":"B97","DOI":"10.1016\/j.vaccine.2007.06.067","article-title":"Lessons from randomized phase III studies with active cancer immunotherapies\u2014outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC)","volume":"25","author":"Finke","year":"2007","journal-title":"Vaccine"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.1100369","article-title":"Cancer immunotherapy: a treatment for the masses","volume":"305","author":"Blattman","year":"2004","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1074-7613(02)00502-2","article-title":"Nature's TRAIL\u2014on a path to cancer immunotherapy","volume":"18","author":"Smyth","year":"2003","journal-title":"Immunity"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/35037728","article-title":"CD95's deadly mission in the immune system","volume":"407","author":"Krammer","year":"2007","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/ni1102-999","article-title":"Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes","volume":"3","author":"Khong","year":"2002","journal-title":"Nat. Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib37","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib38","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1158\/1535-7163.MCT-05-0151","article-title":"Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology","volume":"4","author":"Laheru","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib39","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri1936","article-title":"Cancer despite immunosurveillance: immunoselection and immunosubversion","volume":"6","author":"Zitvogel","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib40","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nri1498","article-title":"Mechanisms and functional significance of tumour-induced dendritic-cell defects","volume":"4","author":"Gabrilovich","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V88.1.41.41","article-title":"Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen","volume":"88","author":"Cardoso","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib42","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood-2003-11-3762","article-title":"CD40 activation of BCP-ALL cells generates IL-10-producing, IL-12-defective APCs that induce allogeneic T-cell anergy","volume":"104","author":"D'Amico","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib43","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1172\/JCI31422","article-title":"Altered macrophage differentiation and immune dysfunction in tumor development","volume":"117","author":"Sica","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy","volume":"90","author":"Korman","year":"2006","journal-title":"Adv Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib46","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib47","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.4049\/jimmunol.178.5.2883","article-title":"Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta","volume":"178","author":"Liu","year":"2007","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib48","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/82771","article-title":"NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway","volume":"1","author":"Terabe","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib49","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib50","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.4049\/jimmunol.174.8.4880","article-title":"STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion","volume":"174","author":"Kusmartsev","year":"2005","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib51","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1172\/JCI28828","article-title":"Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells","volume":"116","author":"Gallina","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib52","doi-asserted-by":"crossref","first-page":"6173","DOI":"10.4049\/jimmunol.163.11.6173","article-title":"Prostaglandin E2 selectively inhibits human CD4+ T cells secreting low amounts of both IL-2 and IL-4","volume":"163","author":"He","year":"1999","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib53","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib54","first-page":"4756","article-title":"Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients","volume":"61","author":"Schmielau","year":"2001","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-0-387-72005-0_22","article-title":"Myeloid-derived suppressor cells","volume":"601","author":"Nagaraj","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib56","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.4049\/jimmunol.175.7.4583","article-title":"Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells","volume":"175","author":"Kusmartsev","year":"2005","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib57","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4049\/jimmunol.179.2.977","article-title":"Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response","volume":"179","author":"Sinha","year":"2007","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib58","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/14712598.7.4.449","article-title":"Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy","volume":"7","author":"Johnson","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib59","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib60","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib61","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nature01112","article-title":"Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation","volume":"419","author":"Groh","year":"2002","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib62","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nature05768","article-title":"Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands","volume":"447","author":"Kaiser","year":"2007","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib63","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1073\/pnas.201398198","article-title":"Blockade of the granzyme B\/perforin pathway through overexpression of the serine protease inhibitor PI-9\/SPI-6 constitutes a mechanism for immune escape by tumors","volume":"98","author":"Medema","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1074-7613(00)80101-6","article-title":"The makings of a tumor rejection antigen","volume":"11","author":"Gilboa","year":"1999","journal-title":"Immunity"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib65","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood.V87.9.3587.bloodjournal8793587","article-title":"Specific human cellular immunity to bcr-abl oncogene-derived peptides","volume":"87","author":"Bocchia","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib66","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood.V88.9.3522.bloodjournal8893522","article-title":"Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide","volume":"88","author":"Bosch","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib67","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood.V81.5.1369.1369","article-title":"Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein PML-RAR alpha present in acute promyelocytic leukemia cells","volume":"81","author":"Gambacorti-Passerini","year":"1993","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib68","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1172\/JCI3126","article-title":"Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia","volume":"102","author":"Yotnda","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib69","doi-asserted-by":"crossref","first-page":"10050","DOI":"10.1158\/0008-5472.CAN-05-1574","article-title":"Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia","volume":"65","author":"Maia","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib70","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/ijc.22224","article-title":"Leukemia-associated antigenic isoforms induce a specific immune response in children with T-ALL","volume":"119","author":"Dohnal","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib71","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2404354","article-title":"BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes","volume":"20","author":"Kessler","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib72","doi-asserted-by":"crossref","first-page":"8799","DOI":"10.1158\/1078-0432.CCR-05-1314","article-title":"T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization","volume":"11","author":"Rezvani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib73","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1007\/s00262-005-0696-z","article-title":"Induction of anti B-cell malignance CTL response by subfamily-shared peptides derived from variable domain of immunoglobulin heavy chain","volume":"54","author":"Xiaoling","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib74","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000121405","article-title":"Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia","volume":"28","author":"Shabani","year":"2007","journal-title":"Tumour Biol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib75","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/sj.leu.2403930","article-title":"Antigen-specific cellular immunotherapy of leukemia","volume":"19","author":"Van Driessche","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib76","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/10428190601101001","article-title":"Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission","volume":"48","author":"Maggio","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib77","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood.V90.5.1927","article-title":"CD40 ligand induces an antileukemia immune response in vivo","volume":"90","author":"Dilloo","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1385\/MO:22:1:079","article-title":"Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children","volume":"22","author":"Posp\u00edsilov\u00e1","year":"2005","journal-title":"Med Oncol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib79","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1089\/hum.1998.9.14-2049","article-title":"Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor","volume":"9","author":"Stripecke","year":"1998","journal-title":"Hum Gene Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib80","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1089\/10430349950017103","article-title":"Combination of CD80 and granulocyt\u1ebdmacrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"10","author":"Stripecke","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib81","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib82","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood.V96.4.1317","article-title":"Lentiviral vectors for efficient delivery of CD80 and granulocyt\u1ebd-macrophage colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses","volume":"96","author":"Stripecke","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib83","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00262-005-0674-5","article-title":"Development of a whole cell vaccine for acute myeloid leukaemia","volume":"55","author":"Cheuk","year":"2006","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib84","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood-2004-07-2556","article-title":"Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes","volume":"105","author":"Biagi","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib85","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1182\/blood.V94.6.2048","article-title":"CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells","volume":"94","author":"Cignetti","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib86","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V93.3.780","article-title":"Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses","volume":"93","author":"Choudhury","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib87","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.4049\/jimmunol.173.4.2855","article-title":"Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that effeciently stimulate T cell responses","volume":"173","author":"Cignetti","year":"2004","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib88","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/intimm\/dxh139","article-title":"Characterization of dendritic-like cells derived from t(9;22) acute lymphoblastic leukemia blasts","volume":"16","author":"Lee","year":"2004","journal-title":"Int Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib89","first-page":"855","article-title":"Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts","volume":"28","author":"Li","year":"2006","journal-title":"Int J Oncol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib90","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/intimm\/dxf036","article-title":"Generation of potent Th1 responses from patients with lymphoid malignancies after differentiation of B lymphocytes into dendritic-like cells","volume":"14","author":"Mohty","year":"2002","journal-title":"Int Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib91","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/sj.leu.2402672","article-title":"CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia","volume":"16","author":"Todisco","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib92","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood-2005-03-1259","article-title":"Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation","volume":"107","author":"Rousseau","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib93","first-page":"1791a","article-title":"Posttransplant immunotherapy with a GMCSF-based tumor vaccine (GVAX) following autologous stem cell transplant (ASCT) for acute myeloid leukemia (AML) [abstract]","volume":"102","author":"Borrello","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib94","doi-asserted-by":"crossref","first-page":"259a","DOI":"10.1182\/blood.V104.11.259.259","article-title":"Vaccination with the PRl leukemia-associated antigen can induce complete remission in patients with myeloid leukemia [abstract]","volume":"104","author":"Qazilbash","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib95","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib96","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WTl (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WTl peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib97","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1200\/JCO.2005.04.4289","article-title":"Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses","volume":"24","author":"Redfern","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib98","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/jnci\/djj358","article-title":"Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma","volume":"98","author":"Inog\u00e8s","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib99","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2141.2006.05997.x","article-title":"Phase I\/II study of vaccination with dendritic-like leukemia cells for the immunotherapy of acute myeloid leukemia","volume":"133","author":"Roddie","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib100","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.4049\/jimmunol.170.10.4905","article-title":"Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells","volume":"170","author":"Nowak","year":"2003","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib101","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib102","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1172\/JCI32446","article-title":"Adoptive T cell therapy for cancer in the clinic","volume":"117","author":"June","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib103","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib104","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm0596-551","article-title":"Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes","volume":"2","author":"Heslop","year":"1996","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib105","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipient","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib106","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/4716","article-title":"In vivo migration and function of transferred HIV-1-specific cytotoxic T cells","volume":"5","author":"Brodie","year":"1999","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib107","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/nm1310","article-title":"Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer","volume":"11","author":"Rapoport","year":"2005","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib108","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1200\/JCO.1998.16.8.2752","article-title":"Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer","volume":"16","author":"Curti","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib109","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstei\u00f1-Barr (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib110","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2141.2001.02760.x","article-title":"A pilot study of combined immunotherapy with autologous adoptive tumour-specific T-cell transfer, vaccination with CD40-activated malignant B cells and interleukin 2","volume":"113","author":"Schultze","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib111","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib112","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1016\/S1525-0016(16)44578-8","article-title":"A first-in-human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T cells for recurrent\/refractory follicular lymphoma","volume":"15","author":"Jensen","year":"2007","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib113","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood.V90.2.549","article-title":"Ex vivo generation of human anti-pre-B leukemia specific autologous cytolytic T cells","volume":"90","author":"Cardoso","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib114","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood.V94.10.3531.422k14_3531_3540","article-title":"Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies","volume":"94","author":"Cardoso","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib115","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1038\/sj.leu.2404390","article-title":"T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy","volume":"20","author":"D'Amico","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib116","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.exphem.2005.12.012","article-title":"Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells","volume":"34","author":"Barbui","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib117","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-2005-872521","article-title":"Adoptive cellular immunotherapy with CD19-specific T cells","volume":"217","author":"R\u00f6ssig","year":"2005","journal-title":"Klin Padiatr"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib118","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2005-09-3904","article-title":"Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy","volume":"107","author":"Serrano","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib119","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1038\/sj.leu.2404329","article-title":"Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells","volume":"20","author":"Numbenjapon","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib120","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin's disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib121","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bcmd.2007.06.018","article-title":"WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells","volume":"40","author":"Stauss","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib122","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1158\/1078-0432.CCR-07-0286","article-title":"Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy","volume":"13","author":"Spaapen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib123","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2006-03-013318","article-title":"Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex","volume":"109","author":"Heemskerk","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib124","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"Kowolik","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib125","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pule","year":"2005","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib126","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt0102-70","article-title":"Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\/CD28 receptor","volume":"20","author":"Maher","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib127","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1089\/hum.2007.028","article-title":"Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains","volume":"18","author":"Wang","year":"2007","journal-title":"Hum Gene Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR chain","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib129","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1182\/blood-2007-02-072843","article-title":"Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor specific cytotoxic T lymphocytes","volume":"110","author":"Quintarelli","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib130","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.4049\/jimmunol.175.11.7226","article-title":"Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine","volume":"175","author":"Hsu","year":"2005","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib131","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1182\/blood-2006-06-029173","article-title":"Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene","volume":"109","author":"Hsu","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib132","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood.V99.6.2009","article-title":"Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy","volume":"99","author":"Rossig","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib133","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/nbt756","article-title":"Dual-specific T cells combine proliferation and antitumor activity","volume":"20","author":"Kershaw","year":"2002","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib134","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.4049\/jimmunol.174.9.5766","article-title":"Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy","volume":"174","author":"Gough","year":"2005","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib135","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib136","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.cji.0000192104.24583.ca","article-title":"Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-receptor","volume":"29","author":"Lacuesta","year":"2006","journal-title":"J Immunother"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib137","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood-2004-08-3337","article-title":"Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis","volume":"105","author":"Dotti","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib138","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/mt.sj.6300122","article-title":"Engineered human tmpk\/AZT as a novel enzyme\/prodrug axis for suicide gene therapy","volume":"15","author":"Sato","year":"2007","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib139","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood-2003-08-2908","article-title":"Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model","volume":"103","author":"Berger","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib140","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib141","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.gt.3303018","article-title":"Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection","volume":"14","author":"Sangiolo","year":"2007","journal-title":"Gene Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib142","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1089\/hum.2006.17.518","article-title":"Coexpression of the uracil phosphoribosyltransferase gene with a chimeric human nerve growth factor receptor\/cytosine deaminase fusion gene, using a single retroviral vector, augments cytotoxicity of transduced human T cells exposed to 5-fluorocytosine","volume":"17","author":"O'Brien","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib143","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/10430340252939087","article-title":"Clinical-scale selection of anti-CD3\/CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor","volume":"13","author":"Orchard","year":"2002","journal-title":"Hum Gene Ther"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib144","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbmt.2007.04.005","article-title":"Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation","volume":"13","author":"Tey","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib145","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood-2006-04-015230","article-title":"The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies","volume":"109","author":"Traversari","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib146","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib147","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/0008-5472.CAN-06-2283","article-title":"Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy","volume":"67","author":"Singh","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib148","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJM200010053431407","article-title":"T-cell function and migration","volume":"343","author":"von Andrian","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib149","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1073\/pnas.96.5.2233","article-title":"Immune surveillance against a solid tumor fails because of immunological ignorance","volume":"96","author":"Ochsenbein","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","article-title":"Immune resistance orchestrated by the tumor microenvironment","volume":"213","author":"Gajewski","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib151","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V83.3.758.758","article-title":"Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells","volume":"83","author":"Manabe","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib152","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1172\/JCI30235","article-title":"Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase","volume":"117","author":"Iwamoto","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib153","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib154","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nrc1365","article-title":"Molecules and mechanisms of the graft-versus-leukaemia effect","volume":"4","author":"Bleakley","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1084\/jem.174.1.27","article-title":"Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes","volume":"174","author":"Falkenburg","year":"1991","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib156","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4049\/jimmunol.158.2.560","article-title":"Recognition of B cell leukemia-associated minor Histocompatibility antigens by CTL","volume":"158","author":"Dolstra","year":"1997","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib157","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1084\/jem.189.2.301","article-title":"A human minor histocompatibility antigen specific for B cell acute lmyphoblastic leukemia","volume":"189","author":"Dolstra","year":"1999","journal-title":"J Exp Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2008.09.004_bib158","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bbmt.2006.10.015","article-title":"Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives","volume":"13","author":"Sandmaier","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib159","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/sj.bmt.1705650","article-title":"Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation","volume":"39","author":"Godder","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.leu.2403671","article-title":"CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis","volume":"19","author":"Fais","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib161","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1084\/jem.191.4.661","article-title":"Differential tumor surveillance by natural killer (NK) and NKT cells","volume":"191","author":"Smyth","year":"2000","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib162","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"unstructured":"Tiribelli M, Sperotto A, Candoni A, Simeone E, Buttignol S, Fanin R. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res. In press.","key":"10.1053\/j.seminhematol.2008.09.004_bib163"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib164","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/j.seminhematol.2008.02.006","article-title":"Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy","volume":"45","author":"Moccia","year":"2008","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib166","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2005.05872.x","article-title":"The role of gemtuzumab ozogamicin in acute leukaemia therapy","volume":"132","author":"Tsimberidou","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib167","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/j.seminoncol.2006.01.025","article-title":"Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia","volume":"33","author":"Rai","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib168","first-page":"305","article-title":"Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin)","volume":"4","author":"White","year":"2004","journal-title":"J Exp Ther Oncol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib169","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1634\/theoncologist.9-2-160","article-title":"Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma","volume":"9","author":"Vose","year":"2004","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib170","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/0008-5472.CAN-06-0018","article-title":"IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic\/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples","volume":"66","author":"Piloto","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib171","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","article-title":"Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia","volume":"21","author":"Dijoseph","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib172","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/pbc.20770","article-title":"Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro","volume":"48","author":"Bieber","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib173","doi-asserted-by":"crossref","first-page":"e2150","DOI":"10.1371\/journal.pone.0002150","article-title":"Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy","volume":"3","author":"Arnon","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2005.07.013","article-title":"The new face of bispecific antibodies: targeting cancer and much more","volume":"34","author":"Lum","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib175","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.exphem.2007.03.015","article-title":"Identification of an overexpressed gene, HSPA4L, the product of which can provoke prevalent humoral immune responses in leukemia patients","volume":"35","author":"Takahashi","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib176","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1055\/s-2006-942273","article-title":"Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL","volume":"218","author":"Gudowius","year":"2006","journal-title":"Klin Padiatr"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib177","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib178","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bmt.1705425","article-title":"Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia","volume":"38","author":"Kebriaei","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib179","first-page":"285","article-title":"Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study","volume":"91","author":"Zenz","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib180","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1172\/JCI25947","article-title":"Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells","volume":"115","author":"Dannull","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib181","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1172\/JCI27745","article-title":"CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells","volume":"116","author":"Quezada","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib182","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1634\/theoncologist.12-7-873","article-title":"Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer","volume":"12","author":"Ribas","year":"2007","journal-title":"Oncologist"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib183","first-page":"300","article-title":"Disruption of T cell regulatory pathways is necessary for immunotherapeutic cure of T cell acute lymphoblastic leukemia in mice","volume":"16","author":"Fiorentino","year":"2005","journal-title":"Eur Cytokine Netw"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib184","doi-asserted-by":"crossref","first-page":"131401","DOI":"10.1073\/pnas.94.24.13140","article-title":"Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy","volume":"94","author":"Porgador","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4049\/jimmunol.168.1.73","article-title":"Requirement for NK cells in CD40 ligand-mediated rejection of Philadelphia chromosome-positive acute lymphoblastic leukemia cells","volume":"168","author":"Gruber","year":"2002","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib186","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1038\/sj.leu.2403985","article-title":"Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD\/SCID mice","volume":"19","author":"Siegler","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib187","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib188","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib189","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2006-07-036509","article-title":"Increased surveillance of cells in mitosis by human NK cells suggests a novel strategy for limiting tumor growth and viral replication","volume":"109","author":"Nolte-'t Hoen","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib190","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib191","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.4049\/jimmunol.174.10.6540","article-title":"Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors","volume":"174","author":"Leung","year":"2005","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib192","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4049\/jimmunol.172.1.644","article-title":"Determinants of antileukemia effects of allogeneic NK cells","volume":"172","author":"Leung","year":"2004","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib193","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bbmt.2006.04.008","article-title":"KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy","volume":"12","author":"Hsu","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib194","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2004-12-4825","article-title":"Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes","volume":"105","author":"Hsu","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib195","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bjc.6603913","article-title":"Inhibitory KIR-HLA receptor-ligand mismatch in autologous haematopoietic stem cell transplantation for solid tumour and lymphoma","volume":"97","author":"Leung","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib196","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14653240310003558","article-title":"Purification of human natural killer cells using a clinical-scale immunomagnetic method","volume":"5","author":"Iyengar","year":"2003","journal-title":"Cytotherapy"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib197","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00262-004-0609-6","article-title":"Phenotype and function of human natural killer cells purified by using a clinical-scale immunomagnetic method","volume":"54","author":"Leung","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib198","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib199","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.exphem.2007.05.018","article-title":"Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal","volume":"35","author":"Marin","year":"2007","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib200","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib201","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.exphem.2006.05.004","article-title":"Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy","volume":"34","author":"Marin","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib202","first-page":"4369","article-title":"Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer","volume":"23","author":"Seya","year":"2003","journal-title":"Anticancer Res"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib203","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.4049\/jimmunol.169.7.3892","article-title":"Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model","volume":"169","author":"Heckelsmiller","year":"2002","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib204","doi-asserted-by":"crossref","first-page":"582a","DOI":"10.1182\/blood.V110.11.582.582","article-title":"Anti-KIR (1-7F9): a fully human monoclonal antibody (mAb) that blocks KIR2DL1, 2 and 3, promoting natural killer (NK) cell-mediated lysis of tumor cells in vitro and in vivo [abstract]","volume":"110","author":"Wagtmann","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2008.09.004_bib205","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/sj.cgt.7700839","article-title":"Recombinant murine interleukin-12 elicits potent antileukemic immune responses in a murine model of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"12","author":"Gruber","year":"2005","journal-title":"Cancer Gene Ther"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196308001479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196308001479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:02Z","timestamp":1758522002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196308001479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":205,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S0037196308001479"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.09.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in Acute Leukemia","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2008.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}